What this test measures
Prostate-specific antigen (PSA) is a serine protease produced by the epithelial cells of the prostate gland. Small amounts leak into the bloodstream normally; larger amounts are released when the prostate is enlarged, inflamed, mechanically disturbed (DRE, cycling, ejaculation), or affected by cancer. The test measures total PSA in serum by immunoassay.
A PSA above 4 ng/mL is the traditional threshold for further evaluation in men under 70, although modern practice increasingly considers age-specific thresholds, PSA velocity (rate of rise), PSA density (per cc of prostate volume), and the free / total ratio.
Why it matters
PSA is the only tumor marker used in any cancer screening discussion, and it is one of the most controversial tests in medicine. The PLCO and ERSPC trials have shown modest mortality benefit but significant harms (overdiagnosis, overtreatment, biopsy complications). USPSTF recommends individualised shared decision-making in men 55–69 and against routine screening from age 70. NCCN supports informed discussion from age 45–50 (earlier with family history or African ancestry).
In Indian urology practice, PSA is widely used for:
• Workup of lower urinary tract symptoms (LUTS) — to help distinguish BPH from possible cancer • Surveillance in men diagnosed with prostate cancer (after surgery / radiation / hormone therapy — PSA should fall to undetectable / very low) • Shared-decision screening in men 45–70 with full discussion of trade-offs
It is not appropriate as a "tick-box" screening test without that conversation — overtreatment of indolent prostate cancers has been a recognised harm.
How to prepare
Avoid ejaculation for 48 hours before the test. Avoid vigorous cycling for 48 hours. Collect the sample before any prostate exam (DRE, ultrasound, biopsy) — these all transiently raise PSA. If you have an active UTI or prostatitis, postpone the test until 4–6 weeks after treatment. Mention 5-alpha-reductase inhibitors (finasteride, dutasteride — halve PSA after 6 months), recent prostate procedures, or current treatment for prostate cancer.
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| Total PSA (ng/mL)[1][2][3][4] | Age-adjusted: 40–49 < 2.5 · 50–59 < 3.5 · 60–69 < 4.5 · 70+ < 6.5 (lab-specific) | Low PSA argues against significant prostate enlargement / cancer. Note: men on finasteride or dutasteride have artificially halved values — double for interpretation. | 4–10 ng/mL ("grey zone"): cancer probability ~ 25–30%. Refine with free / total PSA ratio, PSA density, MRI. 10–20: cancer probability rises. > 20: high cancer suspicion; biopsy strongly considered. Very high (> 100) suggests advanced / metastatic disease. |
PSA interpretation and next steps
| Total PSA (ng/mL) | Typical interpretation | Next step |
|---|---|---|
| < 1 | Very low risk | Repeat in 2–5 years if screening |
| 1 – 4 | Normal for most age groups | Routine follow-up |
| 4 – 10 (grey zone) | ~ 25–30% probability of cancer | Free / total PSA, MRI prostate, possible biopsy |
| 10 – 20 | ~ 50% probability of cancer | MRI + biopsy |
| > 20 | High probability of cancer; possible metastases | Biopsy, staging imaging |
| Rapid rise (> 0.75 / year) | Concerning even within normal range | Workup |
Frequently asked questions
Should every man have a PSA test?
No. PSA screening should follow a shared decision discussion. NCCN supports informed discussion from age 45–50 (earlier with family history of prostate cancer or African ancestry). USPSTF recommends individualised discussion in men 55–69 and against screening from 70. The risks (overdiagnosis, overtreatment, biopsy complications) are real and need to be weighed against the modest mortality benefit.
What if my PSA is 5.2 — do I need a biopsy?
Not immediately. A PSA in the 4–10 range often warrants additional refinement: free / total PSA ratio, PSA density, and multiparametric MRI of the prostate. Biopsy is reserved for MRI-suspicious lesions or persistently rising PSA.
Does a digital rectal exam affect PSA?
A routine DRE causes only a small transient rise. Biopsy, ejaculation, vigorous cycling, and UTI cause larger transient rises. Avoid these for 48 hours before testing where relevant.
How does finasteride affect PSA?
Finasteride and dutasteride (used for BPH and male pattern baldness) reduce PSA by about 50% after 6 months. Doubling the measured PSA gives a value comparable to non-treated men.
When is PSA most useful?
After diagnosis of prostate cancer — to monitor treatment response and recurrence. In men with LUTS — to help distinguish BPH from possible cancer. In informed screening discussion in eligible age groups.
How long does the report take?
Most NABL labs deliver PSA results in 24 hours.
After prostate surgery, what PSA target indicates success?
After radical prostatectomy, PSA should fall to undetectable (< 0.1 ng/mL). A rising PSA after surgery suggests biochemical recurrence and may need imaging and salvage treatment.
Related Oncology / Tumor Markers tests
Tests commonly ordered alongside PROSTATE SPECIFIC ANTIGEN (PSA), or that help interpret an unexpected result.
Sources & references
- NCCN — Prostate Cancer Early Detection · accessed 2026-05-30T00:00:00.000Z
- USPSTF — Prostate Cancer Screening · accessed 2026-05-30T00:00:00.000Z
- American Cancer Society — PSA Testing · accessed 2026-05-30T00:00:00.000Z
- NCBI StatPearls — Prostate-Specific Antigen · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your PROSTATE SPECIFIC ANTIGEN (PSA) test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book PROSTATE SPECIFIC ANTIGEN (PSA) now